Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2008

View Archived Issues

BASF tenders offer to acquire Ciba

Results from PEARL trial with lasofoxifene presented at the ASBMR meeting

AC-100 promotes cartilage regeneration and repair in experimental models in goats

BTG makes recommended all share offer for Protherics

Transdel enrolls first patient in Ketotransdel phase III registration study

ReNeuron presents business update ahead of its 2008 Annual General Meeting

Array BioPharma reports development of soft calineurin inhibitors for atopic dermatitis

Maxygen and Astellas sign agreement for MAXY-4 in autoimmune diseases and transplant rejection

FDA requests 3-month extension on PDUFA deadline to review NovaDel's Zolpimist

Trillium secures new financing to fund development of TTI-1612

SIGA receives additional USD 20 million from the NIAID to develop antiviral ST-246

iBioPharma selects plant-made influenza vaccine as first clinical development candidate

p38alpha inhibitor developed at Abbott demonstrates beneficial activity in arthritis models

Allergy Therapeutics presents positive results from phase III Pollinex Quattro Ragweed study

Bristol-Myers Squibb to commence cash tender offer for ImClone Systems

CytRx completes Innovive acquisition and provides pipeline update

New pharmaceutical aids imparted by Emisphere

EMEA expands orphan medicinal product status for Neo-Bladder Augment

Recent patents describe novel agents for endocrine disorders

Novel asthma/COPD drug candidate AZD-1419 nominated for development

Cangene files MAA in Europe for HepaGam B solution for infusion or injection

Recent patents disclose novel antiinfective agents

Durect grants worldwide rights to Alpharma for Eladur pain patch

Genmab completes recruitment in phase II ofatumumab trial

Labopharm submits NDA to the FDA for DDS-04A to treat major depression

MethylGene and Celgene convert to milestone arrangement for MGCD-0103

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...